Kornimate/medical-research-clean huggingface dataset:
meditation for burnout in pa students

Conditions: Burnout, Student; Feasibility

Summary: this study investigates the feasibility and effects of an app-based mindfulness meditation intervention for pa students.

the purpose of this study is to determine the feasibility of an app-based mindfulness meditation intervention for pa students. the investigators will measure feasibility of using the calm app for 10-minutes a day for four weeks in pa students. feasibility will be measured with acceptability (i.e. satisfaction survey), demand (participation in the app as prescribed), and practicality (i.e., survey). secondly, the investigators will determine the preliminary effects of a 4-week meditation intervention on burnout levels in pa students when compared to a wait list control group. burnout symptoms (primary outcome), mindfulness, stress levels, and depressive symptoms (secondary outcomes) will be measured at baseline and post-intervention (4-weeks). data gathered from this study will inform a future randomized controlled trial to determine the effects of a mindfulness meditation app on burnout in pa students. the information could also be used to design other studies assessing burnout in the workplace. aim 1: determine the feasibility (acceptability, demand, practicality) of using the calm app 10-minutes per day for four weeks in pa students. for the intervention group, our benchmarks will be as follows: 1) acceptability (i.e., satisfaction) ≥70%, 2) demand (i.e., participation in the app as prescribed, intention to use) ≥70%, 3) practicality (i.e., survey) ≥70%. aim 2: determine the preliminary effects of using the calm app 10-minutes per day for four weeks on burnout (primary outcome) mindfulness, stress levels, and depressive symptoms (secondary outcomes) in pa students as compared to a wait-list control group.

Eligibility criteria:
inclusion criteria: * physician assistant students currently enrolled in school who do not practice meditation regularly * \> 18 years of age * able to speak/read/understand english * residing in the u.s. * regular internet access via mobile phone, tablet, etc. * willing to participate in app-based meditation program * burnout, classified as a score greater than or equal to 3 on the non-propriety single item burnout measure. exclusion criteria: * physician assistant students who currently (within the last six months) practice meditation * professionals who identify as a practicing physician assistant * people who are not currently enrolled in physician assistant school * individuals who are not burnt out, classified as a score less than or equal to 2 on the non-propriety single item burnout measure.
desmopressin as treatment for postoperative bleeding after cardiac surgery

Conditions: Hemorrhage; Postoperative Blood Loss

Summary: some patients undergoing cardiac surgery develop excessive postoperative bleeding. cardiopulmonary bypass causes platelet dysfunction. several studies have documented the ability of desmopressin to reduce hemorrhage in a variety of congenital and acquired platelet disorders. in this study the investigators will investigate wether desmopressin reduces postoperative microvascular bleeding. the investigators will investigate wether desmopressin reduces platelet activation as measured by plasma concentration of neutrophil activating peptid 2 and by flow cytometry. the primary endpoint of the study will, however, be total postoperative bleeding and need for transfusions of blood components after surgery. the need for transfusions will be registered during the whole hospital stay. patient with excessive postoperative bleeding (more than 250 ml for one hour, or more than 150ml for two hours during the first four hours) will be randomized into two groups and given either desmopressin or placebo (0,9% sodium chloride) as an intravenous infusion. blood samples for plasma concentration measurements will be drawn before infusion of desmopressin/placebo, immediately after the infusion and 20 hours postoperatively. postoperative bleeding will be registered for 16 hours. the need for any transfusions of blood products will be registered for the whole hospital stay.


Eligibility criteria:
inclusion criteria: * patients above 18 years of age scheduled for cardiac surgery * excessive postoperative bleeding, more than 250 ml for one hour, or more than 150ml for two hours during the first four hours exclusion criteria: * patients younger than 18 years of age * patients with a medical condition known to influence the hemostatic system * patients treated with clopidogrel or systemic steroids during the last week before surgery * patients with inr above 1.5 * patients who are not able to give written informed concent * unstable patients who need other transfusion limits than in this study

Keywords: postoperative hemorrhage hemorrhage vasopressin blood loss, surgical
management of congenial clasped thumb

Conditions: Orthopedic Disorder

Summary: congenital clasped thumb is a rare progressive flexion and adduction deformity presenting with heterogenous congenital abnormalities.(1, 2) it is confused with trigger finger deformity due to fixated flexion deformity of the thumb. in congenital trigger finger entrapment is present at a1 pulley level due to fusiform enlargement of flexor pollicis longus tendon

the main problem is the deficient extensor tendon mechanism of thumb due to functional and structural causes. \\ although in congenital clasp finger deformity there are thumb flexion deformity due to extensor tendon insufficiency and muscle and skin contractions at flexor and thenar regions. in congenital clasped thumb success of treatment depends on lesion type. although successful results have been obtained with splinting and conservative treatment, several reconstruction methods are used due to secondarily developed contractures in neglected cases. tendon transfers are useful in hypermobile thumb cases who have both extensor and opponents tendon deficiency.

Eligibility criteria:
inclusion criteria: 1. congenital clasped thumb 2. cerebral palsy 3. arthrogryposis 4. under age of eight years old. exclusion criteria: * 1- congenital trigger thumb. 2- neglected adducted thumb. 3- post traumatic extensor tendon injury. 4- neglected congenital clasped thumb.
development and piloting of a just-in-time, personalized hiv prevention intervention for youth experiencing homelessness and unstable housing

Conditions: Behavior, Risk

Summary: the purpose of this study is develop and pilot test a personalized hiv intervention with youth experiencing homelessness by creating and field testing prevention messages that address real-time predictors (e.g., sexual urge, use to use drugs, and substance use) of hiv risk behaviors,to evaluate the feasibility and acceptability of the intervention and to evaluate the intervention outcome effects on hiv risk behaviors (e.g., condomless sex, number of sexual partners, pre-exposure prophylaxis(prep) awareness, substance use during sex,intravenous(iv)drug use)


Eligibility criteria:
inclusion criteria: * english speaking * hiv high risk: iv drug user or sexually active youth (sex in the past 3 months) who reports at least one of the following: condomless sex, concurrent sexual partners within 2 weeks,sex with a partner of unknown hiv status, or a bacterial sti in the last 6 months. * homelessness: staying on the streets or in a place not meant for human habitation, a shelter,hotel/motel, or some place they cannot stay for more than 30 days exclusion criteria: * below 6th grade reading level:determined by the rapid estimate of adult literacy in medicine short form (realm)

Keywords: hiv prevention homeless
descriptive study of biological stress and perceived stress at the center 15

Conditions: Physiological Stress; Psychological Stress

Summary: the purpose of this study is to describe biological stress (cortisolemia) and perceived stress in emergency call center operators and doctors while processing a center 15 call.

sample description : qualitative variables be expressed as percentages, numbers and 95% confidence intervals quantitative variables will be expressed as means, standard deviations or medians, range, interquartile intervals description of biological stress : it will be described by calculating the difference between the observed peek or peeks of cortisol ans the cortisol level measured at rest (means, standard deviations or medians, range, interquartile intervals) description of perceived stress : the avs will be described in terms of means and standard deviation comparison of the peek-delta/base level of cortisol in the 3 different workstations of the call center operators according to the non parametrical kruskall wallis test. same for the lengthof service of the call operator, the severity of the call and the status of the doctor the avs score (perceived stress) will be compared to the peek-delta/base level of cortisol (biological stress) thanks to the spearmann correlation coefficient.

Eligibility criteria:
inclusion criteria: * medical and paramedical staff from the center 15 (call operators, emergency doctors and general practitioners) * healthy volunteers having received the specific information letter regarding the sudy and having signed the clarified consent form * healthy volunteers are affiliated to the french social welfare exclusion criteria: * chronic alcoholism * women under oestroprogestative hormonal treatment * high level athletes * healthy volunteers under steroids treatment * healthy volunteers suffering from a mental health related disorder * fever on the day the sample is taken * healthy volunteers with endocrine disorders

Keywords: stress cortisol emergency call center hospital staff
study of neoadjuvant chemotherapeutic treatment (xelox) followed by chemoradiotherapy (xelox/rt) and surgery versus chemoradiotherapy followed by surgery and chemotherapy in patients with high risk rectal cancer

Conditions: Rectal Neoplasms

Summary: primary: * to assess complete pathological response rate of both strategies. secondary: * safety profile * to assess downstaging rate of both strategies. * to compare relative dose intensity of oxaliplatin and capecitabine of both strategies * to compare time to progression and overall survival of both strategies.


Eligibility criteria:
inclusion criteria: * patients with rectal adenocarcinoma. * operable tumour, confirmed by magnetic resonance of high resolution and / or endorectal echography, or, * rectal tumour at distal third, or * tumours spread more than 5 mm in perirectal fat * functional state ecog ≤ 2. * good hematological, hepatic and renal function exclusion criteria: * previous pelvis radiotherapy. * previous antitumoural chemotherapy * pregnant or breastfeeding women. * childbearing women with a positive pregnancy test result at baseline. menopausal women should not have the period for the last 12 months. * history of any other neoplastic illness within the last 5 years, except for already resolved small cell skin cancer or cervix cancer. * clinically significant cardiovascular disease * confirmed peripheral neuropathy. * gastrointestinal disorders or bad absorption syndrome or non-capable to take oral medication. * blood disorders. * intercurrent non-controlled or severe infections. * patients who have undergone major surgery, open biopsies or with significant trauma lesions within the previous 28 days. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
effect of oral supplements on the nutritional status of locally advanced nasopharyngeal carcinoma patients

Conditions: Nasopharyngeal Carcinoma

Summary: malnutrition is very common in locally advanced nasopharyngeal carcinoma(npc) patients undergoing current chemoradiotherapy (crt) due to dysphagia, mucositis, nausea and other treatment-related problems. malnutrition is associated with lower physical functioning, lower immune status, more severe (grade iii/iv) late rt-induced toxicities, treatment interruption of chemo(radio)therapy, lower chemotherapy response rates, hospital readmission, impaired quality of life (qol), and increased mortality. although the international guidelines recommend early nutritional support in the presence of nutritional risk, the best type of nutritional intervention is still unclear. individualized dietary counseling showed beneficial effects in nutritional intake, nutritional status and qol in head and neck cancer patients undergoing rt or crt-treatment; oral nutritional supplements (ons) was most acceptable in chinese npc patients. previous nutritional intervention trials in head-neck cancer patients have been conducted on small samples and did not clarify the role of oral nutritional supplements (ons). accordingly, although current guidelines recommend as grade a the use of ons associated with dietary counseling for head-neck cancer patients undergoing rt, the efficacy of this nutritional intervention still needs to be evaluated in adequately sized and randomized clinical trials for chinese npc patients.


Eligibility criteria:
inclusion criteria: 1. newly diagnosed、pathologically proven nasopharyngeal carcinoma（stage iii/iv） 2. concurrent radiation and chemotherapy(platinum ) 3. karnofsky score over 60 4. no evidence of metastatic disease 5. no significant cardiac, chest, gastrointestinal or renal morbidities exclusion criteria: 1. age \<18 years 2. ongoing artificial nutrition 3. refusal

Keywords: nutritional status nasopharyngeal carcinoma nutritional counseling concurrent chemoradiotherapy oral nutritional supplements
safety and pharmacokinetics of igpro20 and igpro10 in adults with systemic sclerosis (ssc)

Conditions: Diffuse Cutaneous Systemic Sclerosis

Summary: this is a prospective, multicenter, randomized, open-label, crossover study to investigate the safety, tolerability, and pharmacokinetics of igpro20 in participants with diffuse cutaneous systemic sclerosis (dcssc). the pharmacokinetic study aims to evaluate the relative bioavailability of igpro20, and characterize pharmacokinetics of igpro20 and igpro10, respectively, in participants with dcssc. safety, tolerability, and pharmacokinetics of igpro10 will also be evaluated.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years (male or female) at time of providing written informed consent * documented diagnosis of systemic sclerosis (scleroderma) according to american college of rheumatology (acr) and european league against rheumatism (eular) criteria 2013 (diffuse cutaneous form of ssc). * modified rodnan skin score (mrss) ≥ 15 and ≤ 45 at screening * disease duration ≤ 5 years defined as the time from the first non-raynaud's phenomenon manifestation * capable of providing written informed consent and willing and able to adhere to all protocol requirements exclusion criteria: * primary rheumatic autoimmune disease other than dcssc, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disorder, polymyositis, dermatomyositis, as determined by the investigator. note: participants with fibromyalgia, secondary sjogren's syndrome, and scleroderma-associated myopathy at screening are not excluded * participants has mrss \> 2 at the potential subcutaneous (sc) injection sites * history of skin condition precluding sc infusion, or clinical signs and symptoms of a chronic skin disease other than systemic sclerosis or skin manifestation of an allergic disease or other dermatological conditions that would interfere with trial assessments or compromise safety (eg, dermatitis, eczema, psoriasis) * participants has clinical signs and symptoms of skin irritation (eg, pruritus, burning, erythema) or hypo/ hyperpigmentation (eg, scars, tattoos) at the potential sc injection sites * significant pulmonary arterial hypertension as documented by mean pulmonary arterial pressure \> 30 mmhg on right heart catheterization requiring sc or iv prostacyclin or use of dual oral therapies * forced vital capacity \< 50% predicted or a diffusing capacity of the lung for carbon dioxide (dlco) ≤ 40% predicted (corrected for hemoglobin) * a female who is pregnant, breastfeeding, or is a woman of childbearing potential who does not agree to use acceptable methods of contraception; a male who does agree to use acceptable methods of contraception. * evidence of chronic kidney disease with an estimated glomerular filtration rate (egfr) \< 45 ml/min/1.73m2 or if participants are receiving dialysis. participants with current confirmed diagnosis of diabetes mellitus requiring medication with an egfr \< 90 ml/min/1.73m2

Keywords: scleroderma
study of apatinib in ret fusion positive advanced non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: ret fusions are present in 1% to 2% of unselected population of non-small cell lung cancer (nsclc). existing us food and drug administration-approved inhibitors of ret tyrosine kinase show promising therapeutic effects in a non-small cell lung cancer patients. apatinib is an oral multi-kinase inhibitors including ret fusions. this study is designed to evaluate the safety and tolerability of apatinib in patients with ret fusion positive advanced nsclc.

to observe objective response rate (orr) of apatinib in ret fusion positive pre-treated advanced nsclc. to observe progression free survival （pfs）. to assess the overall survival (os). to assess safety and tolerability. to evaluate quality of life. to explore the relationship between biomarkers and the toxicity/efficacy of apatinib.

Eligibility criteria:
inclusion criteria: * aged ≥18 and ≤80 years. * ecog performance status of 0 to 1. * life expectancy of more than 12 weeks. * at least one measurable lesion exists.(recist 1.1) * histologically or cytologic confirmed ret fusion positive advanced non-small cell lung cancer who failed to prior therapies. * required laboratory values including following parameters: anc: ≥ 1.5 x 10\^9/l, platelet count: ≥ 80 x 10\^9/l, hemoglobin: ≥ 90 g/l, total bilirubin: ≤ 1.5 x upper limit of normal, uln, alt and ast: ≤ 1.5 x uln, bun and creatine clearance rate: ≥ 50 ml/min lvef: ≥ 50% qtcf: \< 470 ms * signed informed consent * females of child-bearing potential must have negative serum pregnancy test. sexually active male and those having childbearing potential must practice contraception during the study. exclusion criteria: * squamous carcinoma (including adeno-squamous carcinoma), small cell lung cancer * subjects with third space fluid that can not be controled by drainage or other methods. * obvious cavity or necrosis formed in the tumor * uncontrolled hypertension * hymoptysis, more than 2.5ml daily * thrombosis in 12 months, including pulmonary thrombosis, stroke, or deep venous thrombosis * received big surgery, had bone fracture or ulcer in 4 weeks * urine protein \>++, or urine protein in 24 hours\> 1.0g * pregnant or lactating woman * receiving any other antitumor therapy. * known history of hypersensitivity to apatinib or any of it components.

Keywords: apatinib ret gene fusion non-small cell lung cancer
high-intensity focused ultrasound study

Conditions: Prostate Cancer

Summary: conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. however, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the structures in the proximity. active surveillance carries the risk of disease progression and psychological distress to the patients. focal therapy employs the concept of only destroying the significant lesion, resulting in disease cure and improved functional outcome. among the different options of focal therapy, high-intensity focused ultrasound (hifu) is one of the most commonly employed energy sources. it exerts its effect through thermal and mechanical destruction of cancer tissue. this study aims at assess the effectiveness of such treatment in prostate cancer management. in this study, investigators evaluate the early oncological outcome and objective functional outcome of patients undergoing hifu for the treatment of localized intermediate risk prostate cancer.


Eligibility criteria:
inclusion criteria: * visible index lesion(s) on mri * index lesion(s) greater than 0.5 cm3 * found to have localized low-risk or intermediate-risk prostate cancer after mri-usg fusion targeted biopsy and saturation biopsy: 1. clinical tumour stage t2, or 2. gleason score 7, or 3. psa 20 ng/ml exclusion criteria: * prostate size larger than 50 ml * patients unfit for contrast mri exam * patients with previous treatment of prostate cancer * patients with previous surgery on the prostate * patients with active urinary tract infection * patients with bladder pathology including bladder stone and bladder cancer * patients with urethral stricture * patients with neurogenic bladder and/or sphincter abnormalities * fail to give informed consent

Keywords: prostate cancer focal therapy high-intensity focused ultrasound
eucalimus post-market registry

Conditions: Coronary Arterioscleroses

Summary: to collect post marketing surveillance data on consecutive patients with coronary heart disease intended to be or treated by the eucalimus sirolimus eluting ptca stent when used according to the instructions for use. data will be collected in order to assess the long term safety and performance of the eucalimus ptca stent in routine clinical practice.

the multicenter, prospective registry population consists of consecutive patients with coronary heart disease who undergo percutaneous coronary intervention (pci) and are intended to be or treated by the eucalimus sirolimus eluting ptca stent (according to the instructions for use) as part of routine clinical care. approximately 251 patients from 5-10 centers in europe and asia will be entered into the registry. patients entered into the registry are followed for three years. the registry is considered finished when all patients have completed the 36-month follow-up. a follow-up is scheduled at the following timepoints: immediately post-procedure, 30 days, 6 months, 12 months, 24 months, and 36 months. follow-up is obtained by telephone contact with the patient or at a planned hospital visit.

Eligibility criteria:
inclusion criteria: * consecutive patients intended to be, or treated by eucalimus as per physicians' decision and according to instructions for use (ifu) in the setting of routine clinical care are entered into the registry. exclusion criteria: * patients are excluded from registration if any of the following conditions apply: * high probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons) * currently participating in another investigational drug or device study in which a routine angiographic follow-up is planned * a life expectancy of \<1year * explicit refusal of participation in the registry

Keywords: coronary artery disease coronary disease myocardial ischemia heart diseases arteriosclerosis cardiovascular diseases drug-coated stent ischemic heart disease